Articles

Statistics
  • 106 Articles

红斑狼疮是一种慢性且易反复发作的自身免疫性疾病,常见于20~40岁女性。根据病变部位进行分类,分别为局限在皮肤的皮肤型红斑狼疮(CLE)和累及全身脏器的系统性红斑狼疮(SLE)。

  1.   02 Август 2024
  2.   市场见闻

Lupus erythematosus is a chronic and relapsing autoimmune disease, commonly affecting women aged 20–40 years. Based on the site of pathological involvement, it is classified into cutaneous lupus erythematosus (CLE), which is confined to the skin, and systemic lupus erythematosus (SLE), which affects multiple organs throughout the body.

  1.   02 Август 2024
  2.   Market Insights

人类体内大约具有8%的DNA来自于远古时代的人类先祖所感染的逆转录病毒残余。这种逆转录病毒将自身的RNA逆转录为DNA并整合到遗传物质中一直跟随我们至今。

  1.   25 Јули 2024
  2.   市场见闻

Owing to its multiple advantages, nanobodies have been widely applied and studied in the field of biological research. Beyond the mainstream research directions, they also hold great potential in the fields of food safety and agricultural development. Nowadays, this technology is gradually being applied to research in the field of transdermal...

Owing to its multiple advantages, nanobodies have been widely applied and studied in the field of biological research. Beyond the mainstream research directions, they also hold great potential in the fields of food safety and agricultural development. Nowadays, this technology is gradually being applied to research in the field of transdermal drug delivery.

  1.   19 Јули 2024
  2.   Market Insights

Recently, Ivonescimab Injection, independently developed by Akeso-Sino Biopharmaceutical Co., Ltd. and the world's first of its kind, has been officially approved for marketing. Combined with chemotherapy, Ivonescimab Injection is expected to provide a brand-new and highly effective immunotherapeutic regimen for patients with locally advanced...

Recently, Ivonescimab Injection, independently developed by Akeso-Sino Biopharmaceutical Co., Ltd. and the world's first of its kind, has been officially approved for marketing. Combined with chemotherapy, Ivonescimab Injection is expected to provide a brand-new and highly effective immunotherapeutic regimen for patients with locally advanced or metastatic non-squamous non-small cell lung cancer.

  1.   17 Јуни 2024
  2.   Market Insights
No articles created yet
Unable to load tooltip content.
Support is Offline
Today is our off day. We are taking some rest and will come back stronger tomorrow
Official support hours
Monday To Friday
From 9:00AM To 6:00PM